Literature DB >> 27553987

Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis.

Gabriela Cobo1, Paloma Gallar2, Cristina Di Gioia2, Concepción García Lacalle3, Rosa Camacho2, Isabel Rodriguez2, Olimpia Ortega2, Carmen Mon2, Ana Vigil2, Bengt Lindholm4, Juan Jesús Carrero4.   

Abstract

BACKGROUND: Testosterone deficiency (hypogonadism) is common among men undergoing haemodialysis, but its clinical implications are not well characterized. Testosterone is an anabolic hormone that induces erythrocytosis and muscle synthesis. We hypothesized that testosterone deficiency would be associated with low muscle mass, physical inactivity and higher dosages of erythropoietin-stimulating agents (ESA).
METHODS: Single-center cross-sectional study of 57 male haemodialysis patients. None of the patients was undergoing testosterone replacement therapy. Total testosterone was measured in serum. Body composition (by bioelectrical impedance analysis) and physical activity (by the use of pedometers) were assessed. Patients with testosterone levels below the normal range were considered hypogonadal.
RESULTS: Mean testosterone level was 321±146ng/dL; 20 patients (35%) were hypogonadal. Hypogonadal patients were older and had lower mean arterial blood pressure, higher interleukin-6 levels, lower lean body mass and higher fat body mass. A negative association between testosterone and normalized ESA dose was found in uni- and multivariate regression analyses. Testosterone levels directly correlated with lean body mass regardless of confounders. Hypogonadal patients had lower physical activity than their counterparts [2753±1784 vs. 4291±3225steps/day (p=0.04)]. The relationship between testosterone and physical activity was independent of age, comorbidities and inflammatory markers, but dependent on the proportion of muscle mass.
CONCLUSION: Hypogonadism is common in our male haemodialysis population and is associated with higher ESA doses, reduced muscle mass and lower physical activity. The link between low testosterone levels and physical inactivity may conceivably relate to reduced muscle mass due to inadequate muscle protein synthesis.
Copyright © 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Actividad física; Haemodialysis; Hemodiálisis; Physical activity; Testosterona; Testosterone

Mesh:

Substances:

Year:  2016        PMID: 27553987     DOI: 10.1016/j.nefro.2016.04.009

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  6 in total

1.  The association between serum testosterone and mortality among elderly men on hemodialysis.

Authors:  Hung-Chieh Wu; Lin-Chien Lee; Wei-Jie Wang
Journal:  J Clin Lab Anal       Date:  2018-01-25       Impact factor: 2.352

2.  Daily Step Counts in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Fan Zhang; Yibo Ren; Hui Wang; Yan Bai; Liuyan Huang
Journal:  Front Med (Lausanne)       Date:  2022-02-17

Review 3.  Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease.

Authors:  Katarzyna Romejko; Aleksandra Rymarz; Hanna Sadownik; Stanisław Niemczyk
Journal:  Nutrients       Date:  2022-08-21       Impact factor: 6.706

4.  Efficacy of Testosterone Treatment in Hemodialysis Patients as Assessed by Aging Males' Symptoms Scores: A Pilot Study.

Authors:  Yasuyuki Inoue; Kenzo Nakamura; Yoshitaka Kuwahara; Yan Lu; Nanako Masuda; Shigeo Horie; Hiroshi Okada; Hisamitsu Ide
Journal:  Am J Mens Health       Date:  2018-05-03

5.  Advanced Chronic Kidney Disease is a Strong Predictor of Hypogonadism and is Associated with Decreased Lean Tissue Mass.

Authors:  Ryszard Skiba; Anna Matyjek; Tomasz Syryło; Stanisław Niemczyk; Aleksandra Rymarz
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-11-05

6.  Missed Diagnoses and Health Problems in Adults With Prader-Willi Syndrome: Recommendations for Screening and Treatment.

Authors:  Karlijn Pellikaan; Anna G W Rosenberg; Anja A Kattentidt-Mouravieva; Rogier Kersseboom; Anja G Bos-Roubos; José M C Veen-Roelofs; Nina van Wieringen; Franciska M E Hoekstra; Sjoerd A A van den Berg; Aart Jan van der Lely; Laura C G de Graaff
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.